BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 26378953)

  • 21. In-hospital switching from clopidogrel to prasugrel following thrombolysis for ST-elevation myocardial infarction: a 3-year single center experience.
    Lerman TT; Zahger D; Arad J; Gilutz H; Reitblat O; Shimony A
    Eur Heart J Acute Cardiovasc Care; 2016 Jun; 5(3):271-6. PubMed ID: 25904758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of prasugrel pre-treatment strategy in patients undergoing percutaneous coronary intervention for NSTEMI: the ACCOAST-PCI study.
    Montalescot G; Collet JP; Ecollan P; Bolognese L; Ten Berg J; Dudek D; Hamm C; Widimsky P; Tanguay JF; Goldstein P; Brown E; Miller DL; LeNarz L; Vicaut E;
    J Am Coll Cardiol; 2014 Dec; 64(24):2563-2571. PubMed ID: 25524333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of therapeutic hypothermia on on-treatment platelet reactivity and clinical outcome in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction: Results from the ISAR-SHOCK registry.
    Orban M; Mayer K; Morath T; Bernlochner I; Hadamitzky M; Braun S; Schulz S; Hoppmann P; Hausleiter J; Tiroch K; Mehilli J; Schunkert H; Massberg S; Laugwitz KL; Sibbing D; Kastrati A
    Thromb Res; 2015 Jul; 136(1):87-93. PubMed ID: 25976448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction.
    Schulz S; Richardt G; Laugwitz KL; Morath T; Neudecker J; Hoppmann P; Mehran R; Gershlick AH; Tölg R; Anette Fiedler K; Abdel-Wahab M; Kufner S; Schneider S; Schunkert H; Ibrahim T; Mehilli J; Kastrati A;
    Eur Heart J; 2014 Sep; 35(34):2285-94. PubMed ID: 24816809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study.
    Ferri LA; Morici N; Grosseto D; Tortorella G; Bossi I; Sganzerla P; Cacucci M; Sibilio G; Tondi S; Toso A; Ferrario M; Gandolfo N; Ravera A; Mariani M; Corrada E; Di Ascenzo L; Petronio AS; Cavallini C; Moffa N; De Servi S; Savonitto S
    Am Heart J; 2016 Nov; 181():101-106. PubMed ID: 27823681
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial.
    Wiviott SD; White HD; Ohman EM; Fox KA; Armstrong PW; Prabhakaran D; Hafley G; Lokhnygina Y; Boden WE; Hamm C; Clemmensen P; Nicolau JC; Menozzi A; Ruzyllo W; Widimsky P; Oto A; Leiva-Pons J; Pavlides G; Winters KJ; Roe MT; Bhatt DL
    Lancet; 2013 Aug; 382(9892):605-13. PubMed ID: 23953385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy.
    Pride YB; Wiviott SD; Buros JL; Zorkun C; Tariq MU; Antman EM; Braunwald E; Gibson CM;
    Am Heart J; 2009 Sep; 158(3):e21-6. PubMed ID: 19699846
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Upstream clopidogrel, prasugrel, or ticagrelor for patients treated with primary angioplasty: Results of an angiographic randomized pilot study.
    Mont'Alverne-Filho JR; Rodrigues-Sobrinho CR; Medeiros F; Falcão FC; Falcão JL; Silva RC; Croce KJ; Nicolau JC; Valgimigli M; Serruys PW; Lemos PA
    Catheter Cardiovasc Interv; 2016 Jun; 87(7):1187-93. PubMed ID: 26614123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of a combination of antiplatelet and antithrombotic pretreatment on myocardial perfusion in patients with an acute ST-segment elevation myocardial infarction undergoing a primary percutaneous coronary intervention.
    Prech M; Bartela E; Janus M; Jeremicz I; Araszkiewicz A; Urbanska L; Pyda M; Grajek S
    Coron Artery Dis; 2016 Nov; 27(7):580-5. PubMed ID: 27228184
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety of Prasugrel Compared With Clopidogrel for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
    Wang A; Lella LK; Brener SJ
    Am J Ther; 2016; 23(6):e1637-e1643. PubMed ID: 24942006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study.
    Parodi G; Bellandi B; Valenti R; Migliorini A; Marcucci R; Carrabba N; Giurlani L; Gensini GF; Abbate R; Antoniucci D
    Am Heart J; 2014 Jun; 167(6):909-14. PubMed ID: 24890542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).
    Wiviott SD; Antman EM; Gibson CM; Montalescot G; Riesmeyer J; Weerakkody G; Winters KJ; Warmke JW; McCabe CH; Braunwald E;
    Am Heart J; 2006 Oct; 152(4):627-35. PubMed ID: 16996826
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prehospital administration of P2Y12 inhibitors and early coronary reperfusion in primary PCI: an observational comparative study.
    De Backer O; Ratcovich H; Biasco L; Pedersen F; Helqvist S; Saunamäki K; Tilsted HH; Clemmensen P; Olivecrona G; Kelbaek H; Jørgensen E; Engstrøm T; Holmvang L
    Thromb Haemost; 2015 Aug; 114(3):623-31. PubMed ID: 25994355
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prasugrel versus clopidogrel in acute coronary syndromes treated with PCI: Effects on clinical outcome according to culprit artery location.
    De Servi S; Goedicke J; Ferlini M; Palmerini T; Syvänne M; Montalescot G
    Int J Cardiol; 2016 Nov; 223():632-638. PubMed ID: 27565841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Angiographic and platelet reactivity outcomes with prasugrel 60 mg pretreatment and clopidogrel 600 mg pretreatment in primary percutaneous coronary intervention.
    Li Y; Tai BC; Sia W; Phua QH; Richards MA; Low A; Chan KH; Teo SG; Sim TB; Lee CH; Roe MT; Yeo TC; Tan HC; Chan MY
    J Thromb Thrombolysis; 2012 Nov; 34(4):499-505. PubMed ID: 22855283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment.
    Shoji S; Sawano M; Sandhu AT; Heidenreich PA; Shiraishi Y; Ikemura N; Ueno K; Suzuki M; Numasawa Y; Fukuda K; Kohsaka S
    JAMA Netw Open; 2020 Apr; 3(4):e202004. PubMed ID: 32239221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of prasugrel versus clopidogrel in Korean patients with acute myocardial infarction undergoing successful revascularization.
    Park KH; Jeong MH; Kim HK; Ahn TH; Seung KB; Oh DJ; Choi DJ; Kim HS; Gwon HC; Seong IW; Hwang KK; Chae SC; Kim KB; Kim YJ; Cha KS; Oh SK; Chae JK;
    J Cardiol; 2018 Jan; 71(1):36-43. PubMed ID: 28673508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use, efficacy and safety of prasugrel in patients with ST segment elevation myocardial infarction scheduled for primary percutaneous coronary intervention in clinical practice. Results of the prospective ATACS-registry.
    Zeymer U; Hochadel M; Lauer B; Kaul N; Wöhrle J; Andresen D; Schwimmbeck P; Solzbach U; Thiele H; Gitt A; Diller F; Zahn R
    Int J Cardiol; 2015 Apr; 184():122-127. PubMed ID: 25703419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Loh JP; Pendyala LK; Kitabata H; Torguson R; Chen F; Kent KM; Satler LF; Suddath WO; Pichard AD; Waksman R
    Am J Cardiol; 2013 Mar; 111(6):841-5. PubMed ID: 23273719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
    Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW
    Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.